التفاصيل البيبلوغرافية
| العنوان: |
Transcatheter aortic valve implantation versus surgical aortic valve replacement in severe aortic stenosis patients at low surgical mortality risk: a cost-effectiveness analysis in Belgium. |
| المؤلفون: |
Dubois, Christophe, Adriaenssens, Tom, Annemans, Lieven, Bosmans, Johan, Callebaut, Britt, Candolfi, Pascal, Cornelis, Kristoff, Delbaere, Alexis, Green, Michelle, Kefer, Joelle, Lancellotti, Patrizio, Rosseel, Michael, Shore, Judith, Van Der Heyden, Jan, Vermeersch, Sebastian, Wyffels, Eric |
| المصدر: |
Acta Cardiologica; Feb2024, Vol. 79 Issue 1, p46-57, 12p |
| مصطلحات موضوعية: |
HEART valve prosthesis implantation, AORTIC valve transplantation, AORTIC stenosis, QUALITY of life, RISK assessment, AORTIC valve insufficiency, QUALITY-adjusted life years |
| مصطلحات جغرافية: |
BELGIUM |
| مستخلص: |
Transcatheter aortic valve implantation (TAVI) with the SAPIEN 3 device has recently shown significant clinical benefits, compared to surgical aortic valve replacement (SAVR), in patients at low risk for surgical mortality (PARTNER 3 trial, NCT02675114). Currently in Belgium, TAVI use is restricted to high-risk or inoperable patients with severe symptomatic aortic stenosis (sSAS). This cost-utility analysis aimed to assess whether TAVI with SAPIEN 3 could lead to potential cost-savings compared with SAVR, in the low-risk sSAS population in Belgium. A previously published, two-stage, Markov-based cost-utility model was used. Clinical outcomes were captured using data from PARTNER 3 and the model was adapted for the Belgian context using cost data from the perspective of the Belgian National Healthcare System, indexed to 2022. A lifetime horizon was chosen. The model outputs included changes in direct healthcare costs, survival and health-related quality of life using TAVI versus SAVR. TAVI with SAPIEN 3 provides meaningful clinical and cost benefits over SAVR, in terms of an increase in quality-adjusted life years (QALYs) of 0.94 and cost-saving of €3 013 per patient. While initial procedure costs were higher for TAVI compared with SAVR, costs related to rehabilitation, disabling stroke, treated atrial fibrillation, and rehospitalization were lower. The cost-effectiveness of TAVI over SAVR remained robust in sensitivity analyses. TAVI with SAPIEN 3 may offer a meaningful alternative intervention to SAVR in Belgian low-risk patients with sSAS, showing both clinical benefits and cost savings associated with post-procedure patient management. [ABSTRACT FROM AUTHOR] |
|
Copyright of Acta Cardiologica is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
